baber/WOPTO huggingface dataset:
Patent NZ-227083-A (NZ)
Title: Pharmaceutical compositions containing buprenorphine and naltrexone
Inventor: LEWIS JOHN WILLIAM
IPC: A61K31/485
Filed: 1988-11-25
Abstract: A pharmaceutical composition in sublingual unit dosage form for maintenance treatment of opiate addicts comprising from 2 to 8mg buprenorphine and an amount of naltrexone sufficient to substantially attenuate the euphorigenic effect of the buprenorphine when injected and to provide greater opiate blocking effect than that of naltrexone alone.
Patent NZ-232375-A (NZ)
Title: Insulin analogues modified at b29
Inventor: CHANCE RONALD EUGENE
IPC: C07K/
Filed: 1990-02-05
Abstract: Analogs of human insulin modified at position 29 of the B chain thereof and, optionally, at other positions, have modified physico-chemical and pharmacokinetic properties and are useful in the treatment of hyperglycemia. The insulin analogs are of the formula <IMAGE> or a pharmaceutically acceptable salt thereof, wherein A21 is alanine, asparagine, aspartic acid, glutamine, glutamic acid, glycine, threonine, or serine; B1 is phenylalanine, aspartic acid, or is absent; B2 is valine or may be absent when B1 is absent; B3 is asparagine or aspartic acid; B9 is serine or aspartic acid; B10 is histidine or aspartic acid; B27 is threonine or is absent; B28 is any amino acid, B29 is L-proline, D-proline, D-hydroxyproline, L-hydroxyproline, L-(N-methyllysine), D-lysine, L-(N-methylarginine) or D-arginine; B30 is alanine, threonine or is absent; Z is -OH, -NH2, -OCH3, or -OCH2CH3; X is Arg, Arg-Arg, Lys, Lys-Lys, Arg-Lys, Lys-Arg, or is absent; and Y may be present only when X is present and, if present, is Glu or an amino acid sequence which comprises all or a portion of the sequence <IMAGE>  and which begins at the N-terminus Glu of such sequence; provided that when A21 is asparagine, B1 is phenylalanine, B2 is valine, B3 is asparagine, B9 is serine, B10 is histidine, B27 is threonine, B28 is lysine, B29 is L-proline, B30 is threonine, X is absent and Y is absent, then Z is -NH2, -OCH3 or -OCH2CH3.
Patent NZ-237709-A (NZ)
Title: Substituted cycloalkano-dihydroindoles, preparation and pharmaceutical compositions thereof
Inventor: MULLER ULRICH E
IPC: A61P11/00
Filed: 1991-04-05
Abstract: Cycloalkano[b]dihydroindoles and -indolesulphonamides substituted by heterocycles can be prepared by reaction of corresponding indoles with acrylonitrile and subsequent hydrolysis of the cyanoethyl compounds or by reaction of corresponding hydrazines with cycloalkanones. The cycloalkano[b]dihydroindoles and -indolesulphonamides substituted by heterocycles can be used as active compounds in medicaments, in particular for the treatment of thromboembolisms, ischaemias, asthma and allergies.
Patent NZ-239262-A (NZ)
Title: Flexible razor head having one piece moulding around blades.
Inventor: CHEN EVAN N
IPC: B26B21/14
Filed: 1991-08-05
Abstract: An integrally formed flexible razor head (10) having a plurality of blade platforms (70) separated by a corrugation (60), at least one blade (20 or 30) having a cutting edge (21 or 31), and a plurality of blade retainers (40) which are integrally formed with the blade platforms (70) and extend to positions above and adjacent to the top surface of the blade (20,30). While the blade retainers (40) are integrally formed with the other pieces of the flexible razor head (10), each blade retainer (40) is discrete with respect to other blade retainers (40). <IMAGE>
Patent NZ-252686-A (NZ)
Title: Herbicidal composition comprising n-(2-(3,3,3,-trifluoropropyl)-phenylsulphonyl]-n'-(4-methoxy-6 -methyl-1,3,5-triazin-2-yl)urea and a synergistic amount of at least one of various other herbicides
Inventor: GUT HANS
IPC: A01N47/36
Filed: 1993-04-23
Abstract: Herbicidal composition comprising N-[2-(3,3,3-trifluoropropyl)-phenylsulfonyl]-N'-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-urea of the formula I    <IMAGE>  (I)  or agrochemically tolerated salts thereof, and a synergistic amount of another active substance 3,5-dibromo-4-hydroxybenzonitrile of the formula II    <IMAGE>  (II)
Patent NZ-256255-A (NZ)
Title: Protein allergen of der p ii, and pharmaceutical compositions containing them
Inventor: THOMAS WAYNE R
IPC: C07K14/54
Filed: 1993-09-10
Abstract: The present invention features isolated DNA encoding allergens of Dermatophagoides (house dust mites) particularly of the species Dermatophagoides farinae and Dermatophagoides pteronyssinus, which are protein allergens or peptides which include at least one epitope of the protein allergen. In particular, the invention provides DNA encoding the major D. farinae allergens, Der f I and Der f II and DNA encoding the major D. pteronvssinus allergens, Der p I and Der p II. The present invention further relates to proteins and peptides encoded by the isolated D. farinae and D. pteronvssinus DNA, including proteins containing sequence polymorphisms. In addition, the proteins or peptides encoded by the isolated DNA, their use a diagnostic and therapeutic reagents and methods of diagnosing and treating sensitivity to house dust mite allergens, are disclosed.
Patent NZ-260622-A (NZ)
Title: Synergistic fungicidal compositions containing 8-t-butyl-2-(n-ethyl-n-n-propylamino)-methyl-1,4-dioxaspiro[4 .5]decane and other named fungicide(s)
Inventor: DUTZMANN STEFAN
IPC: A01N43/36
Filed: 1994-05-30
Abstract: Fungicidal synergistic active agent (substance) combinations of the known aminomethyl heterocycle of the formula (I) <IMAGE> on the one hand, and on the other hand, known fungicidal active agents.
Patent NZ-264038-A (NZ)
Title: (thia)-cycloalkyl[b]indoles and medicaments thereof
Inventor: CAUBERE PAUL
IPC: A61P9/00
Filed: 1994-07-19
Abstract: The invention relates to the compounds of formula (I): <IMAGE>  in which R1, R2, R3 and A are as defined in the description. Medicaments.
Patent NZ-264307-A (NZ)
Title: 2-(alkyl, halogens, cyano, or fluoroalkyl) benzoguanidines preparation and pharmaceutical compositions thereof
Inventor: WEICHERT ANDREAS
IPC: C07D233/60
Filed: 1994-08-25
Abstract: There are described ortho-substituted benzoylguanidines of the formula I <IMAGE>  in which:   R(1) is H, Hal, CN, NO2, (cyclo)alkyl, (O)(S)[NR(5)](CH2)b-(CF2)c-CF3,   R(5) is H, (C1-C4)-alkyl, -CdH2dR(6),   R(6) is cycloalkyl, (bi)phenyl(yl), naphthyl,  or   R(1) is -SR(10), -OR(10), -CR(10)R(11)R(12),   R(10) is -CfH2f-(C3-C8)-cycloalkyl, -(C1-C9)-heteroaryl or phenyl, R(11) and R(12) are defined as R(10) or are hydrogen, (C1-C4)-alkyl,  or   R(1) is naphthyl, (bi)phenyl(yl), (C1-C9)-heteroaryl,  or R(1) is -SR(13), -OR(13), -NHR(13), -NR(13)R(14), -CHR(13)R(15), -C[R(15)R(16)]OH, -C IDENTICAL CR(18), -C[R(19)]=CR(18), -[CR(20)R(21)]k-(CO)-[CR(22)R(23)R(24)]l,   R(13) and R(14) are -(CH2)g-(CHOH)h-(CH2)l-(CHOH)j-R(17),   R(17) is hydrogen, methyl, -(CH2)g-O-(CH2-CH2O)h-R(24), R(15) and R(16) are hydrogen, alkyl or, together with the carbon atom carrying them, cycloalkyl,   R(18) is phenyl, heteroaryl, (cyclo)alkyl,   R(19), R(20), R(21), R(22) and R(23) are hydrogen, methyl,   R(24) is H, (cyclo)alkyl, -CmH2m-R(18),   R(2) and R(3) are defined as R(1),   R(4) is alkyl, Hal, CN, -(CH2)n-(CF2)o-CF3,  and their pharmaceutically tolerable salts. Compounds I have no unwanted salidiuretic properties, but very good antiarrhythmic properties. They are outstandingly suitable as antiarrhythmic medicaments having a cardioprotective component for infarct prophylaxis and infarct treatment and for the treatment of angina pectoris, where they also preventively inhibit or greatly decrease the pathophysiological processes in the formation of ischaemically induced damage. Because of their protective actions against pathological hypoxic and ischaemic situations, the compounds of the formula I according to the invention, as a result of inhibition of the cellular Na<+>/H<+> exchange mechanism, can be used as medicaments for the treatment of all acute or chronic damage caused by ischaemia or illnesses primarily or secondarily induced thereby.
Patent NZ-268601-A (NZ)
Title: Postal sorting using images of addresses or id tags
Inventor: REICH KARL
IPC: G06V30/10
Filed: 1994-07-04
Abstract: In this method, in which   - the despatches travel through successive scanning means for generating a video image of each despatch, a mechanical storage path and a printing station, - the video images are supplied to first means for reading the address information and for allocating a corresponding code, the despatches, for which the address information was read within a predetermined time, are provided with the corresponding code in the printing station and the video images of the despatches, for which the address information has not been automatically read within the predetermined time, are supplied to video coding stations for reading the address information and for allocating a corresponding code, and - despatches which are not provided with a corresponding code are provided with an ID tag and - code and ID tag are stored in order to provide the relevant despatches with the code at a later time,  the following steps are carried out:   - the video image of each despatch for which the address information is not automatically read within the predetermined time, is stored in a buffer from which the most recent video image of which is supplied to the video coding stations, despatches, to which a corresponding code is thereupon allocated before the despatch reaches the printing station, being provided with the code in the printing station, - the remaining despatches are provided with an ID tag in the printing station.   <IMAGE>
Patent NZ-280219-A (NZ)
Title: Cancer treatment with toremefine or one of its metabolites
Inventor: DEGREGORIO MICHAEL WILLIAM
IPC: A61K47/48
Filed: 1993-03-25
Abstract: PCT No. PCT/FI93/00119 Sec. 371 Date Oct. 31, 1994 Sec. 102(e) Date Oct. 31, 1994 PCT Filed Mar. 25, 1993 PCT Pub. No. WO93/19746 PCT Pub. Date Oct. 14, 1993Transdermal preparations containing as active ingredient toremifene or one of its metabolites N-demethyltoremifene or 4-hydroxy-toremifene or their pharmaceutically acceptable non-toxic salts are useful for the treatment of cancers localized in the skin or on a short distance form the skin such as metastatic lesions of breast cancer. They may also be used in adjuvant therapy of breast cancer and in the reversal of multidrug resistance of cancer cells to cytotoxic drugs. Such transdernal preparations are of particular interest in the treatment of melanoma, lymphoma, Kaposi's sarcoma and fungoides mycosis.
Patent NZ-292319-A (NZ)
Title: Delivery of exogenous chemical agent to non-woody plant tissue at a site where local physical injury is effected
Inventor: BODULOVIC ZELJKO
IPC: A01N25/00
Filed: 1995-08-14
Abstract: The present invention relates to an improved method for delivering an effective amount of exogenous chemical substance or substances to a plant or plants via non-woody living tissues thereof. Also disclosed are novel compositions which are particularly useful by the method of the invention, apparatus for delivering exogenous chemical substances by the method of the invention, and a leaf prepared by this invention. This invention involves the use of a propelled material to cause local physical injury to non-woody living tissues before, simultaneously with or after application of the exogenous chemical substance. Benefits of the enhanced delivery achieved by practice of the present invention include, but are not restricted to, lower use rates, better rainfastness and more rapid manifestation of the effect of the exogenous chemical substance.
Patent NZ-296562-A (NZ)
Title: Recombinant peptides and secretory mehods for their preparation
Inventor: NGOC THIEN NGUYEN
IPC: A61K35/76
Filed: 1995-11-07
Abstract: A method for secreting a biologically active recombinant peptide as an analogue of a natural peptide having at least one hydrophobic region, by culturing cells transformed by a nucleic acid construct comprising elements for the expression and secretion of the peptide by the cell, and a sequence coding for a peptide with an amino acid sequence that differs from the natural peptide sequence in that it has at least one modification in a non-transmembrane hydrophobic region of the peptide; and by recovering the peptide and/or cells carrying the recombinant peptide. The resulting recombinant peptide, a corresponding DNA sequence, and a bacterium containing same, are also disclosed.
Patent NZ-305699-A (NZ)
Title: Vascular endothelial cell growth factor (VEGF) antagonists useful for the treatment of age-related macular degeneration
Inventor: FERRARA NAPOLEONE
IPC: A61K38/18
Filed: 1996-03-28
Abstract: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, as well as other diseases and disorders characterized by undesirable or excessive neovascularization. This invention relates to the use of VEGF in the preparation of medicaments.
Patent NZ-305893-A (NZ)
Title: Pharmaceutical composition comprising a polymeric release material, active ingredient, a transcutaneous absorption promotor and a non-aqueous solvent which forms a flexible film on contact with skin
Inventor: SAUNAL HENRY
IPC: A61P25/00
Filed: 1996-03-29
Abstract: This pharmaceutical composition for transdermal delivery comprises: (a)	optionally a polymeric release matrix capable of forming a flexible film after drying selected from cellulose polymers or copolymers; (b)	an active principle; (c)	15-30% by weight of a transcutaneous absorption promoter for the active principle and (d)	a physiologically acceptable non-aqueous solvent capable of dissolving the release matrix, the active principle and the transcutaneous absorption promoter, and quickly removing same by evaporation on contact with the skin. The transcutaneous absorption promoter is an aliphatic fatty acid ester which is soluble in the physiologically acceptable non-aqueous solvent and has the formula R-C(O)-O-R1 or an aliphatic fatty alcohol which is soluble in the physiologically acceptable non-aqueous solvent and has the formula R2-O-H wherein R, R1 and R2 are as defined in the specification.
Patent NZ-320194-A (NZ)
Title: Process for preparing a flexible polyurethane foam
Inventor: VAN ESSCHE LUC
IPC: C08G101/00
Filed: 1996-10-10
Abstract: rocess for preparing a flexible polyurethane foam by reacting a)  a polyisocyanate composition having an NCO value of 11-24 % by weight with b)	an isocyanate-reactive compound having a number average molecular weight of 1000-12000 using c)	water as blowing agent; and optionally d)	a catalyst; and optionally e)	other auxilaries and additives disclosed in the specification.
Patent NZ-320237-A (NZ)
Title: Stable pharmaceutical forms of administration containing parathormone
Inventor: VON BUEREN HENDRIK
IPC: A61P19/10
Filed: 1996-10-17
Abstract: Pharmaceutical preparations in the form of a lyphilisate or injection or infusion solution and that are stable during storage contain a parathyroid hormone or parathyroid hormone fragment as an active substance and a basic amino acid and optionally an organic or inorganic physiologically tolerated acid.  The preparations are free of physiologically tolerated antioxidants.
Patent NZ-325395-A (NZ)
Title: Switch status sensor that distinguishes between false on/off events caused by electromagnetic noise and true on/off events
Inventor: ALLCORN ROGER
IPC: H01H9/16
Filed: 1997-01-09
Abstract: A switch status sensor is provided for counting on/off events of a switch of a water meter. When an on/off event is detected by a microcontroller, the microcontroller supplies a "signature" signal, which is distinguishable from electromagnetic noise, to the switch. If this "signature" signal is detected as having passed through the switch by the microcontroller, then it can be confirmed that the switch is closed. Alternatively, if the "signature" signal is not detected as having passed through the switch by the microcontroller, then it is verified that the switch is open. Thus, the switch status sensor can distinguish between false switch events caused by electromagnetic noise and true on/off events of the switch.
Patent NZ-329585-A (NZ)
Title: Apparatus for collecting bee venom, square wave pulses applied to wire electrodes at hive entrance
Inventor: NIKOLAEV NIKOLAI SERGUEEVICH
IPC: A01K57/00
Filed: 1999-04-08
Abstract: An apparatus for collecting bee venom includes spaced wires 306 to  which a pulsed square wave voltage is applied.  A tensioned insulating mesh separates the bees from the wires.  The pulsed electric field from the wires irritates the bees and causes them to sting through the mesh onto a glass collector plate 305.  As the mesh does not grip the stings, the bees do not die after depositing their venom.  The pulses applied to the wires are unipolar square waves with duration of 10 - 2000 microseconds and a pulse separation of 3 - 50 milliseconds.  The voltage can be between 100 and 1000V.
Patent NZ-331178-A (NZ)
Title: Auxiliary free agglomerates of beta-lactam antibiotics
Inventor: RANEBURGER JOHANNES
IPC: A61K31/42
Filed: 1997-03-13
Abstract: Beta-lactam antibiotics are formed as auxiliary-free agglomerates that may be formed directly into tablets.  The antibiotics include penicillin V potassium, amoxicillin trihydrate, or cephalexin monohydrate.  The formation of the agglomerates includes forming a paste of the antibiotic with a liquid, kneading the paste at a temperature of 10 degrees Celsius to 80 degrees Celsius, extruding the paste in a double screwed extruder, and drying of the agglomerate.  Particular bulk density and grain size distributions of the agglomerates are disclosed.
Patent NZ-332711-A (NZ)
Title: Biphenylsulfonylamino carboxylic acid derivatives as matrix metalloproteinase inhibitors
Inventor: O'BRIEN PATRICK MICHAEL
IPC: A61P9/10
Filed: 1997-04-24
Abstract: The specification describes compounds of formula (I) above, wherein R1 includes alkyl, halo, nitro, amino, cyano, alkoxy, and alkoxycarbonyl; R2 is alkyl and substituted alkyl; and R3 is OH or NHOH. Preferred compounds are outlined by formula (II). The compounds are useful for inhibiting matrix metalloproteinase enzymes in animals, and as such, prevent and treat diseases resulting from the breakdown of connective tissues.
Patent NZ-336351-A (NZ)
Title: Oriented coextruded films useful in wrapping and packaging comprising a first layer containing only ethylene copolymer having density of 0.9-0.935 g/cm3
Inventor: BRANT PATRICK
IPC: C08K5/20
Filed: 1998-02-24
Abstract: An orientated multi-layer film comprising at least one outer layer comprising from 50-100% of an ethylene copolymer having a density of 0.900-0.935 g/cm3 and a composition distribution breadth index (CDBI) of 50-95% and 0-50 wt % of a different but compatible ethylene homopolymer or copolymer. At least one outer layer is in contact with a polypropylene layer, the film being a co-extrusion of the first ethylene outer layer and the second polypropylene layer. Preferably the ethylene copolymer outer or skin layer has a MWD (Mw/Mn) of 1.8-3.5 and a MI of 0.5-10 (ASTM D 1238, 190oC, 2.16 kg). The co-extruded layers can be biaxially orientated on center frame equipment without difficulties caused by the presence of low molecular weight amorphous polymer fractions inherently present in traditional Ziegler-Natta linear low-density propylene. The ethylene copolymer heat seal layer thus offers a practical, economical solution for preparing heat seal BOPP for all stiff, flexible and heat shrinkable packaging.
Patent NZ-500686-A (NZ)
Title: A method and a system for determination of the number of somatic cells in milk, utilizing electromagnetic radiation
Inventor: HANSEN FRANS EJNER RAVN
IPC: G01N21/59
Filed: 1998-05-05
Abstract: Described is a diagnostic method for assessing the number of somatic cells in a liquid milk or milk product analyte.  The method comprises: (i) arranging a volume of a liquid sample representing the analyte material in a sample compartment and (ii) allowing electromagnetic signals from the sample in the compartment to pass through and be exposed to the exterior. This results in exposing onto an array of active detection elements at least a one-dimensional spatial representation of electromagnetic signals from the sample. The representation is detectable by individual active detection elements. Representations of electromagnetic signals from the somatic cells are  identified. The size of the volume of the liquid sample is sufficiently large to permit the assessment of the number of somatic cells.
Patent NZ-501646-A (NZ)
Title: Use of 2-mercapto-pyridine-N-oxide its salts and metal complexes for the preservation of animal skins and leather
Inventor: KUGLER MARTIN
IPC: C14C9/00
Filed: 1998-06-02
Abstract: The use of mercapto-pyridine-N-oxide and/or its alkaline earth salts, and its metal complexes for preserving animal skins and leather is described. The mercapto-pyridine-N-oxide in combination with a phenolic active ingredient is suitable for the protection and preservation of animal skins and feathers. Wet chrome leathers treated with the combination incubated for 28 days at 95% relative humidity at 20-30 degrees Celsius exhibited no mould growth after at least 28 days.
Patent NZ-501922-A (NZ)
Title: Creating zonal isolation between the interior and exterior of a well system
Inventor: CUMMING FRANCIS ALEXANDER
IPC: E21B41/00
Filed: 1998-07-31
Abstract: A method is provided for creating a zonal isolation between the exterior and interior of an uncased section of an underground well system which is located adjacent to a well section in which a well casing is present. The method comprises inserting an expandable tubular through the existing well casing into an uncased section, such as a lateral branch, of the underground well system and subsequently expanding the expandable tubular such that said one end is pressed towards the wall of the uncased section of the well system and the outer surface of said other end is pressed against the inner surface of the well casing thereby creating an interference fit capable of achieving a shear bond and a hydraulic seal between said surrounding surfaces.
Patent NZ-504608-A (NZ)
Title: Magnesium pressure casting with metal injected in viscous or semi-solid state
Inventor: MURRAY MORRIS TAYLOR
IPC: B22D17/22
Filed: 1998-11-30
Abstract: A metal flow system for use in pressure casting of magnesium alloy in a semi-solid or thixotropic state, with a pressure casting machine having a supply of the alloy in a molten state and a mould or die which defines a die cavity, of a metal flow system which includes a die or mould tool means which defines at least one runner from which molten magnesium alloy is able to be injected into the die cavity. The metal flow system is of a form providing for control of metal flow velocities within the flow system, whereby substantially all of the metal flowing throughout the die cavity is in a semi-solid state, and the above mentioned form results from the system including at least one controlled expansion region in which the metal flow is able to spread laterally, with respect to its direction of injection, with the resultant reduction in its flow velocity relative to its velocity in the runner, whereby the state of the alloy is changed from the molten state to a semi-solid state.  Filling of the die cavity is able to proceed progressively by semi-solid fronts of metal moving away from a gate or other site of injection, and the flow of magnesium alloy from the runner may be via at least one controlled expansion region of the metal flow system.